José Bonilla-Delgado

Dr. José Bonilla-Delgado

Research Unit, Hospital Regional de Alta Especialidad de Ixtapaluca, Mexico City, Ciudad de México, Mexico
orcid

Research Focus & Metrics

Academic Career Length

19Years (2008-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
9 June 2014 in Journal of Cellular Physiology
Verified
Journal Article
Closed access
PDF file
VGVicky García‐Hernández
Vicky García‐Hernández
CFCatalina Flores‐Maldonado
Catalina Flores‐Maldonado
RRRuth Rincón-Heredia
Ruth Rincón-Heredia
OVOdette Verdejo‐Torres
Odette Verdejo‐Torres
José Bonilla-DelgadoJosé Bonilla-Delgado
José Bonilla-Delgado
RCRubén G. Contreras
Rubén G. Contreras

1 February 2012 in Molecular Cancer Research
Verified
Journal Article
Open access
PDF file
José Bonilla-DelgadoJosé Bonilla-Delgado
José Bonilla-Delgado
GBGülay Bulut
Gülay Bulut
XLXuefeng Liu
Xuefeng Liu
ENOC MARIANO CORTÉS MALAGÓNENOC MARIANO CORTÉS MALAGÓN
ENOC MARIANO CORTÉS MALAGÓN
RSRichard Schlegel
Richard Schlegel
PGPatricio Gariglio
Patricio Gariglio
The contribution of the Wnt signaling pathway to human papilloma virus (HPV)-induced carcinogenesis is poorly understood. In high-grade dysplastic lesions that are caused by high-risk HPVs (HR-HPV), β-catenin is often located in the cell nucleus, which suggests that Wnt pathway may be involved in the development of HPV-related carcinomas. Most of the oncogenic potential of HR-HPVs resides on the PDZ-binding domain of E6 protein. We hypothesized that the PDZ-binding domain of the HPV16-E6 oncoprotein induces the nuclear accumulation of β-catenin due to its capacity to degrade PDZ-containing cellular targets. To test this hypothesis, we evaluated the staining pattern of β-catenin in the skin epidermis of transgenic mice expressing the full-length E6 oncoprotein (K14E6 mice) and measured LacZ gene expression in K14E6 mice that were crossed with a strain expressing LacZ that was knocked into the Axin2 locus (Axin2+/LacZ mice). Here, we show that the E6 oncoprotein enhances the nuclear accumulation of β-catenin, the accumulation of cellular β-catenin–responsive genes, and the expression of LacZ. None of these effects were observed when a truncated E6 oncoprotein that lacks the PDZ-binding domain was expressed alone (K14E6ΔPDZ mice) or in combination with Axin2+/LacZ. Conversely, cotransfection with either E6 or E6ΔPDZ similarly enhanced canonical Wnt signaling in short-term in vitro assays that used a luciferase Wnt/β-catenin/TCF-dependent promoter. We propose that the activation of canonical Wnt signaling could be induced by the HPV16-E6 oncoprotein; however, the participation of the E6 PDZ-binding domain seems to be important in in vivo models only. Mol Cancer Res; 10(2); 250–8. ©2011 AACR.

1 January 2014 in Experimental Cell Research
Verified
Journal Article
Closed access
RRRuth Rincón-Heredia
Ruth Rincón-Heredia
DFDavid Flores-Benitez
David Flores-Benitez
CFCatalina Flores-Maldonado
Catalina Flores-Maldonado
José Bonilla-DelgadoJosé Bonilla-Delgado
José Bonilla-Delgado
VGVicky García-Hernández
Vicky García-Hernández
RCRubén G. Contreras
Rubén G. Contreras

Verified
Journal Article
Open access
PDF file
ILICELA PALMA LARA
ICELA PALMA LARA
MPMonserrat Pérez-Ramírez
Monserrat Pérez-Ramírez
PAPatricia García Alonso-Themann
Patricia García Alonso-Themann
AEAna María Espinosa-García
Ana María Espinosa-García
RGRicardo Godinez-Aguilar
Ricardo Godinez-Aguilar
CPCarmen Palacios-Reyes
Carmen Palacios-Reyes
FAM20C is a gene coding for a protein kinase that targets S-X-E/pS motifs on different phosphoproteins belonging to diverse tissues. Pathogenic variants of FAM20C are responsible for Raine syndrome (RS), initially described as a lethal and congenital osteosclerotic dysplasia characterized by generalized atherosclerosis with periosteal bone formation, characteristic facial dysmorphisms and intracerebral calcifications. The aim of this review is to give an overview of targets and variants of FAM20C as well as RS aspects. We performed a wide phenotypic review focusing on clinical aspects and differences between all lethal (LRS) and non-lethal (NLRS) reported cases, besides the FAM20C pathogenic variant description for each. As new targets of FAM20C kinase have been identified, we reviewed FAM20C targets and their functions in bone and other tissues, with emphasis on novel targets not previously considered. We found the classic lethal and milder non-lethal phenotypes. The milder phenotype is defined by a large spectrum ranging from osteonecrosis to osteosclerosis with additional congenital defects or intellectual disability in some cases. We discuss our current understanding of FAM20C deficiency, its mechanism in RS through classic FAM20C targets in bone tissue and its potential biological relevance through novel targets in non-bone tissues.

1 December 2013 in Virology
Verified
Journal Article
Closed access
ENOC MARIANO CORTÉS MALAGÓNENOC MARIANO CORTÉS MALAGÓN
ENOC MARIANO CORTÉS MALAGÓN
José Bonilla-DelgadoJosé Bonilla-Delgado
José Bonilla-Delgado
Jose Diaz-ChavezJose Diaz-Chavez
Jose Diaz-Chavez
AHAlfredo Hidalgo-Miranda
Alfredo Hidalgo-Miranda
SRSandra Lorena Romero-Cordoba
Sandra Lorena Romero-Cordoba
PGPatricio Gariglio
Patricio Gariglio

23 September 2024 in Brain Sciences
Verified
Journal Article
Open access
PDF file
ENOC MARIANO CORTÉS MALAGÓNENOC MARIANO CORTÉS MALAGÓN
ENOC MARIANO CORTÉS MALAGÓN
ALAdolfo López-Ornelas
Adolfo López-Ornelas
IGIrlanda Olvera Gómez
Irlanda Olvera Gómez
José Bonilla-DelgadoJosé Bonilla-Delgado
José Bonilla-Delgado
Alzheimer’s disease (AD) is the leading cause of dementia, mainly affecting elderly individuals. AD is characterized by β-amyloid plaques, abnormal tau tangles, neuronal loss, and metabolic disruptions. Recent studies have revealed the involvement of the kynurenine (KP) pathway and the aryl hydrocarbon receptor (AhR) in AD development. The KP pathway metabolizes tryptophan to produce neuroactive substances like kynurenine, kynurenic acid, and quinolinic acid. In AD, high levels of kynurenine and the neurotoxic quinolinic acid are associated with increased neuroinflammation and excitotoxicity; conversely, reduced levels of kynurenic acid, which acts as a glutamate receptor antagonist, compromise neuroprotection. Research has indicated elevated KP metabolites and enzymes in the hippocampus of AD patients and other tissues such as blood, cerebrospinal fluid, and urine. However, the finding that KP metabolites are AD biomarkers in blood, cerebrospinal fluid, and urine has been controversial. This controversy, stemming from the lack of consideration of the specific stage of AD, details of the patient’s treatment, cognitive deficits, and psychiatric comorbidities, underscores the need for more comprehensive research. AhR, a ligand-activated transcription factor, regulates immune response, oxidative stress, and xenobiotic metabolism. Various ligands, including tryptophan metabolites, can activate it. Some studies suggest that AhR activation contributes to AD, while others propose that it provides neuroprotection. This discrepancy may be explained by the specific ligands that activate AhR, highlighting the complex relationship between the KP pathway, AhR activation, and AD, where the same pathway can produce both neuroprotective and harmful effects.